Literature DB >> 1359905

Identification of aspartic acid 514 through glutamic acid 542 as a glycoprotein Ib-IX complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand factor by ristocetin and botrocetin.

M C Berndt1, C M Ward, W J Booth, P A Castaldi, A V Mazurov, R K Andrews.   

Abstract

As the first step in hemostasis, the binding of von Willebrand factor (vWF) to the platelet membrane glycoprotein (GP) Ib-IX complex is essential for platelet adhesion at high-shear blood flow. This interaction in vivo requires the prior binding of vWF to the subendothelial matrix, a process which exposes a normally cryptic binding site on vWF for the GP Ib-IX complex. This process can be mimicked in vitro by modulators such as ristocetin or the snake venom protein botrocetin or by desialation of vWF. We have previously localized the GP Ib binding site on vWF to a monomeric dispase fragment which extends from Leu-480/Val-481 to Gly-718 in the primary sequence of mature vWF [Andrews, R. K., Gorman, J. J., Booth, W. J., Corino, G. L., Castaldi, P. A., & Berndt, M. C. (1989) Biochemistry 28, 8326-8336]. This fragment also contains a distinct binding site for botrocetin. Analysis of synthetic peptides corresponding to hydrophilic stretches of sequence within this fragment indicated that the sequence Asp-514-Glu-542 represents a major adhesive sequence involved in receptor recognition. This peptide inhibited both the ristocetin- and botrocetin-mediated binding of vWF to either platelets or purified GP Ib-IX complex (IC50 approximately 50-200 microM) as well as the asialo-vWF- and bovine vWF-dependent agglutination of platelets. Both the N- and C-terminal halves of the peptide were inhibitory but less so than the intact peptide. This peptide also inhibited botrocetin binding to vWF, suggesting that botrocetin modulates vWF-GP Ib interaction by binding in close proximity to the vWF adhesion sequence.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359905     DOI: 10.1021/bi00160a027

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Dynamic force spectroscopy of glycoprotein Ib-IX and von Willebrand factor.

Authors:  Maneesh Arya; Anatoly B Kolomeisky; Gabriel M Romo; Miguel A Cruz; José A López; Bahman Anvari
Journal:  Biophys J       Date:  2005-03-11       Impact factor: 4.033

2.  Delimiting the autoinhibitory module of von Willebrand factor.

Authors:  W Deng; K M Voos; J K Colucci; E R Legan; E A Ortlund; P Lollar; R Li
Journal:  J Thromb Haemost       Date:  2018-08-16       Impact factor: 5.824

3.  von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure.

Authors:  L Holmberg; J A Dent; R Schneppenheim; U Budde; J Ware; Z M Ruggeri
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

4.  Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function.

Authors:  V H Flood; K D Friedman; J C Gill; P A Morateck; J S Wren; J P Scott; R R Montgomery
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

5.  The role of Akt in the signaling pathway of the glycoprotein Ib-IX induced platelet activation.

Authors:  Hong Yin; Aleksandra Stojanovic; Nissim Hay; Xiaoping Du
Journal:  Blood       Date:  2007-10-03       Impact factor: 22.113

6.  Src family tyrosine kinase Lyn mediates VWF/GPIb-IX-induced platelet activation via the cGMP signaling pathway.

Authors:  Hong Yin; Junling Liu; Zhenyu Li; Michael C Berndt; Clifford A Lowell; Xiaoping Du
Journal:  Blood       Date:  2008-06-11       Impact factor: 22.113

7.  Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin.

Authors:  M F Hoylaerts; K Nuyts; K Peerlinck; H Deckmyn; J Vermylen
Journal:  Biochem J       Date:  1995-03-01       Impact factor: 3.857

Review 8.  Shear-Dependent Platelet Aggregation: Mechanisms and Therapeutic Opportunities.

Authors:  Akshita Rana; Erik Westein; Be'eri Niego; Christoph E Hagemeyer
Journal:  Front Cardiovasc Med       Date:  2019-09-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.